BNP Paribas Asset Management
TSHA icon

BNP Paribas Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

BNP Paribas Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Sell
2,099
-355
-14% -$2.1K ﹤0.01% 2128
2026
Q1 		$11K Buy
+2,454
New +$11.4K ﹤0.01% 2188

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BNP Paribas Asset Management's TSHA Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Taysha Gene Therapies (TSHA) stake by 14% in Q2 2026, selling an estimated $2.1K and leaving 2,099 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2128.

BNP Paribas Asset Management first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • BNP Paribas Asset Management held 2,099 shares of Taysha Gene Therapies worth $14.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 355 Taysha Gene Therapies shares in Q2 2026, an estimated $2.1K.
  • Taysha Gene Therapies made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2128 holding.
  • BNP Paribas Asset Management first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.